Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025
23 Abril 2025 - 7:00AM
Aclarion, Inc.,
(“Aclarion” or the “Company”) (Nasdaq:
ACON, ACONW), a healthcare technology company that is
leveraging biomarkers and proprietary augmented intelligence (AI)
algorithms to help physicians identify the location of chronic low
back pain, will be presenting at the Planet MicroCap Showcase:
VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23,
2025 at 12:30 PM ET.
Brent Ness, Chief Executive Officer of Aclarion, will be
presenting on the Company and recent value-driving initiatives.
In conjunction with the event, Aclarion has published its
updated investor presentation, which can be found on its website at
https://investors.aclarion.com/.
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy (“MRS”), proprietary signal
processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first
addressing the chronic low back pain market with Nociscan, the
first, evidence-supported, SaaS platform to noninvasively help
physicians distinguish between painful and nonpainful discs in the
lumbar spine. Through a cloud connection, Nociscan receives
magnetic resonance spectroscopy (MRS) data from an MRI machine for
each lumbar disc being evaluated. In the cloud, proprietary signal
processing techniques extract and quantify chemical biomarkers
demonstrated to be associated with disc pain. Biomarker data is
entered into proprietary algorithms to indicate if a disc may be a
source of pain. When used with other diagnostic tools, Nociscan
provides critical insights into the location of a patient’s low
back pain, giving physicians clarity to optimize treatment
strategies. For more information, please
visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934 about the Company’s current
expectations about future results, performance, prospects and
opportunities. Statements that are not historical facts, such as
“anticipates,” “believes” and “expects” or similar expressions, are
forward-looking statements. These forward-looking statements are
based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could
significantly affect the Company’s current plans and expectations,
as well as future results of operations and financial condition.
These and other risks and uncertainties are discussed more fully in
our filings with the Securities and Exchange Commission. Readers
are encouraged to review the section titled “Risk Factors” in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2024, as well as other disclosures contained in the Prospectus
and subsequent filings made with the Securities and Exchange
Commission. Forward-looking statements contained in this
announcement are made as of this date and the Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Investor Contacts:
Kirin M. SmithPCG Advisory, Inc.ksmith@pcgadvisory.com
Media Contact:
Jennie KimSPRIG Consultingjennie@sprigconsulting.com
Aclarion (NASDAQ:ACON)
Gráfico Histórico do Ativo
De Abr 2025 até Mai 2025
Aclarion (NASDAQ:ACON)
Gráfico Histórico do Ativo
De Mai 2024 até Mai 2025